Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
On Friday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.6 which represents a slight increase of $0.05 or 1.96% from the prior close of $2.55. The stock opened at $2.55 and ...
GlobalData on MSN7d
Alector stock drops after Alzheimer’s drug fails in Phase II trial"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...
7d
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
Alector (ALEC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeffrey Hung from Morgan Stanley downgraded the rating on the stock to a Sell and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback